Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that TEPEZZA® (teprotumumab-trbw) was selected as a 2020 R&D World R&D 100 Award recipient in the Process/Prototyping category. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of Thyroid Eye Disease (TED). “TEPEZZA is a testament to our focus on developing and manufacturing new medicines for people with rare diseases and we are honored that R&